ORLANDO, Fla.--(BUSINESS WIRE)--Imprivata® (HIMSS14 booth #2541), a leading provider of authentication and access management solutions for the healthcare industry, and DrFirst (HIMSS14 booth #1891), a leading provider of healthcare IT solutions services designed to improve clinical outcomes for patients, today announced a partnership to deliver a combined solution for integration of providers authentication into the electronic prescribing of controlled substances (EPCS) workflow. The companies will focus on the integration of Imprivata’s two-factor authentication management capabilities with DrFirst’s EPCS GoldSM solution to enable providers to more efficiently and securely prescribe controlled substances electronically.
“Imprivata’s partnership with DrFirst brings together two key components for electronic prescribing of controlled substances—DrFirst offers a best-of-breed solution for facilitating the ePrescribing process and provider identity-proofing, and Imprivata delivers strong authentication to identify and authorize care providers,” said Geoff Hogan, senior vice president of business development at Imprivata. “Imprivata is a leader in authentication management and is excited to help providers understand the Drug Enforcement Administration’s (DEA) interim final rule for ePrescribing of controlled substances and implement secure technology solutions that address the regulation while providing the convenience prescribers want.”
Imprivata offers a variety of options for two-factor authentication, including fingerprint biometric identification that complies with FIPS-201 standards. Providers can quickly and securely access workstations, roaming desktops and clinical applications to streamline clinical workflow and enable ePrescribing of controlled substances. DrFirst’s EPCS Gold solution gives providers a platform for signing and sending prescriptions of controlled substances electronically. EPCS Gold includes provider authentication and registration as well as a controlled substance signing module.
“EPCS Gold is a fully certified, scalable solution that meets the DEA requirements for allowing the electronic prescribing of controlled substances,” said G. Cameron Deemer, president of DrFirst. “Integrating with Imprivata will enhance our offering by giving customers a broader choice of two-factor authentication options to use for ePrescribing of controlled substances. We look forward to working closely with Imprivata to bring solutions to market that enable fast, efficient and secure physician authentication.”
About Imprivata
Imprivata is a leading provider of
authentication and access management solutions for the healthcare
industry. Imprivata’s single sign-on, authentication management and
secure communications solutions enable fast, secure and more efficient
access to healthcare information technology systems to address multiple
security challenges and improve provider productivity for better focus
on patient care. For more information, please visit www.imprivata.com.
About DrFirst
DrFirst pioneers technology solutions that
inform the doctor-patient point of encounter, optimizing provider access
to patient information, enhancing the doctor’s clinical view of the
patient, and improving care delivery and clinical outcomes. Our growth
is driven by a commitment to innovation, security, and reliability
across a wide array of services, including Medication Management,
Medication Adherence, and Secure Communication and Collaboration. We are
proud of our track record of service to more than 300 EMR/EHR/HIS
vendors and an extensive network of providers, hospitals and patients.
For more information please visit www.drfirst.com.
All Imprivata products are trademarks of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
